Navigation Links
Symmetry Medical Reports Preliminary Fourth Quarter Revenue
Date:2/14/2008

Provides Full Year 2008 Revenue Guidance of $350 million to $360 million

WARSAW, Ind., Feb. 14 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), an independent provider of products to the global orthopedic device industry and other medical markets, today reported preliminary fourth quarter 2007 revenue of $79.1 million. The Company stated that additional financial results will not be reported at this time.

As previously announced on October 4, 2007, the Company's Audit Committee has undertaken a review of the accounting irregularities uncovered at its Sheffield UK operating unit and that review is continuing. The review to date is substantially complete and has not yielded evidence that persons outside the Sheffield, UK operating unit were aware of the irregularities there, nor has it identified misstatements at the company's other business units, although certain procedures are not yet complete. Symmetry Medical plans to file its Form 10-K for fiscal year 2007, which will include restated financial statements for its fiscal years ended 2005 and 2006, with the Securities and Exchange Commission in March 2008.

Brian Moore, President and Chief Executive Officer, stated, "We continue to be encouraged by the overall strength of the orthopedic markets and the uptake in orders across our global network. We believe that we are well positioned to meet any increased demand from our orthopedic customers, confirming our decision to sustain capacity during periods of slower industry growth. We believe the continued demand for our Total Solutions offering reflects our comprehensive offering and ability to respond quickly to our customers' needs. Our recent acquisition of DePuy's orthopedic instrument facility further expan
'/>"/>

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
2. Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7, 2007
3. Symmetry Medical Reports Preliminary Third Quarter Revenue
4. Symmetry Medical Expands Board of Directors
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
8. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
11. ATS Medical Expands Open Pivot Heart Valve Offerings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... report follows the broad definition of a biomarker ... and evaluated as an indicator of normal biological ... to a therapeutic intervention. Tests based on biomarkers ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 ... in Personalized Medicine, is excited to announce the ... Testing to Optimize the Management of Pain”. , ... at Medscape.com for the next year. The focus ... how to recognize inadequate pain treatments, integrate appropriate ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
(Date:3/3/2015)... TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. ... therapeutics and molecular diagnostics that target the underlying mechanisms ... and seventh-month period ended December 31, 2014. ... year end from May 31 to December 31. As ... reporting today are for the quarter and the seven ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... release of it,s advanced nutritional supplement, Caplex, ... unique patent pending formulation created by an ... cancer patients a comprehensive source of the most ... results accumulated from medical research. Impressive changes in ...
... of Standards and Technology (NIST) have demonstrated a new ... intersection while keeping their cool. Ten million times cooler ... described in a forthcoming paper in Physical Review ... technology to build a large-scale quantum computer using ions ...
... Sinobiopharma Pharmaceutical Group (OTC Bulletin Board: SNBP) ... Yan Tan as Director of Marketing.Ms. Tan joins ... served as a China-based Unit Marketing Director for ... to Organon, Ms. Tan held senior marketing management ...
Cached Biology Technology:Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option 2X marks the spot: Ions coldly go through NIST trap junction 2Sinobiopharma, Inc. Appoints New Director of Marketing 2
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... NEW YORK (DECEMBER 30, 2008)The Bronx Zoo-based Wildlife Conservation Society ... region in South America have paid off in the form ... by the Government of Argentina. ... which became official earlier this month, protects half a million ...
... E or a combination of the supplements had a similar ... supplements, according to data from a randomized controlled trial in ... the National Cancer Institute. Epidemiological studies have suggested ... and thus antioxidants, may have a lower risk of cancer. ...
... COLUMBUS, Ohio Researchers at The Ohio State University ... in leukemia and lung cancer is also important in ... mainly children. The study shows that immature ... mature, and that the molecule is nearly missing in ...
Cached Biology News:A happy new year for penguins 2Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial 2Study links molecule to muscle maturation, muscle cancer 2
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Yersinia pestis...
Biology Products: